Self-emulsifying cannabidiol formulations
The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.
1. A self-emulsifying cannabidiol composition consisting essentially of
from about 5% to about 35% w/w cannabidiol,
from about 40% to about 99% w/w of one or more surfactants,
from about 0.1% to about 2% w/w of an antioxidant, and
one or more cosolvents selected from the group consisting of propylene glycol, polyethylene glycol, and ethanol,
which does not comprise sesame oil, castor oil, olive oil, or water, and wherein the composition,
(i) forms an emulsion having an average globule size from about 30 to about 600 nanometers in less than 30 minutes when dispersed in gastric fluid, and
(ii) has the pharmacokinetic profile between 0 and 8 hours shown in FIG. 2 following a single oral administration of said composition to beagle dogs at a dose equivalent to 200 mg cannabidiol.
2. The self-emulsifying composition of claim 1 , wherein said one or more surfactants is selected from the group consisting of polyethylene glycol 40 hydrogenated castor oil, caprylocaproyl polyoxyl-8 glycerides, linoleoyl polyoxyl-6 glycerides, polyglyceryl-3 dioleate, and polysorbate 80.
3. The self-emulsifying composition of claim 1 , further consisting essentially of one or more oils selected from the group consisting of glyceryl monolinoleate, glyceryl monooleate, propylene glycol dicaprylocaprate, glycerol monostearate 40-55, and a medium chain triglyceride.
4. The self-emulsifying composition of claim 1 , wherein said antioxidant is selected from the group consisting of alpha tocopherol, butylated hydroxy anisole, butylated hydroxy toluene, ascorbyl palmitate, ascorbic acid, sodium ascorbate, sodium metabisulfite, EDTA, citric acid, sodium bisulfite, sodium thiosulfate, thioglycerol, and propyl gallate.
5. The self-emulsifying composition of claim 1 , wherein the composition is contained in a hard gelatin or soft gelatin capsule.
6. A method of treating a disease selected from the group consisting of Prader-Willi syndrome, obesity, graft versus host disease, gelastic seizures/hypothalamic hamartoma, neonatal seizures, dystonia, central pain syndromes, phantom limb pain, multiple sclerosis, traumatic brain injury, acute graft versus host disease, chronic graft versus host disease, T-cell autoimmune disorders, colitis, Dravet Syndrome, Lennox Gastaut Syndrome, mycolonic seizures, juvenile mycolonic epilepsy, refractory epilepsy, childhood absence epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's Disease, autism, acne, Parkinson's disease, social anxiety disorder, depression, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, ischemic injury of heart, ischemic injury of brain, chronic pain syndrome, and rheumatoid arthritis comprising administering a self-emulsifying composition of claim 1 to a subject in need thereof.
7. A method of treating withdrawal symptoms comprising administering a self-emulsifying composition of claim 1 to a subject in need thereof.
8. The method of claim 7 , wherein the withdrawal symptoms are caused by the subject reducing or quitting use of an opioid, cocaine, heroin, an amphetamine or nicotine.
9. A method of reducing the use of an opioid, cocaine, heroin, an amphetamine, or nicotine, comprising administering a self-emulsifying composition of claim 1 to a subject in need thereof.
10. A self-emulsifying cannabidiol composition consisting essentially of
from about 5% to about 35% w/w cannabidiol,
from about 40% to about 99% w/w of a surfactant, and,
from about 0.1% to about 2% w/w of an antioxidant, and
one or more cosolvents selected from the group consisting of propylene glycol, polyethylene glycol, and ethanol,
which does not comprise sesame oil, castor oil, olive oil, or water, and wherein the composition,
(i) forms an emulsion having an average globule size from about 30 to about 600 nanometers in less than 30 minutes when dispersed in gastric fluid, and
(ii) has a pharmacokinetic profile in which the single mean plasma concentration peak for cannabidiol has an area under the curve (AUC) 0-8 of about 3448 ng-hr/mL, Cmax of about 673 ng/mL, and a Tmax of about 3 hours, following a single oral administration of said composition to beagle dogs at a dose equivalent to 200 mg cannabidiol.
11. The self-emulsifying composition of claim 10 , wherein said surfactant is selected from the group consisting of polyethylene glycol 40 hydrogenated castor oil, caprylocaproyl polyoxyl-8 glycerides, linoleoyl polyoxyl-6 glycerides, polyglyceryl-3 dioleate, and polysorbate 80.
12. The self-emulsifying composition of claim 10 , further consisting essentially of one or more oils selected from the group consisting of glyceryl monolinoleate, glyceryl monooleate, propylene glycol dicaprylocaprate, glycerol monostearate 40-55, and a medium chain triglyceride.
13. The self-emulsifying composition of claim 10 , wherein said surfactant is selected from the group consisting of alpha tocopherol, butylated hydroxy anisole, butylated hydroxy toluene, ascorbyl palmitate, ascorbic acid, sodium ascorbate, sodium metabisulfite, EDTA, citric acid, sodium bisulfite, sodium thiosulfate, thioglycerol, and propyl gallate.
14. The self-emulsifying composition of claim 10 , wherein the composition is contained in a hard gelatin or soft gelatin capsule.
15. A method of treating a disease selected from the group consisting of Prader-Willi syndrome, obesity, graft versus host disease, gelastic seizures/hypothalamic hamartoma, neonatal seizures, dystonia, central pain syndromes, phantom limb pain, multiple sclerosis, traumatic brain injury, acute graft versus host disease, chronic graft versus host disease, T-cell autoimmune disorders, colitis, Dravet Syndrome, Lennox Gastaut Syndrome, mycolonic seizures, juvenile mycolonic epilepsy, refractory epilepsy, childhood absence epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's Disease, autism, acne, Parkinson's disease, social anxiety disorder, depression, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, ischemic injury of heart, ischemic injury of brain, chronic pain syndrome, and rheumatoid arthritis comprising administering a self-emulsifying composition of claim 10 to a subject in need thereof.
16. A method of treating withdrawal symptoms comprising administering a self-emulsifying composition of claim 10 to a subject in need thereof.
17. The method of claim 16 , wherein the withdrawal symptoms are caused by the subject reducing or quitting use of an opioid, cocaine, heroin, an amphetamine or nicotine.
18. A method of reducing the use of an opioid, cocaine, heroin, an amphetamine, or nicotine, comprising administering a self-emulsifying composition of claim 10 to a subject in need thereof.